Introduction
Angiogenesis, the formation of new blood vessels, is an essential process during growth and progression of solid tumors. Vascular endothelial growth factor (VEGF) is a well-known stimulator of tumor angiogenesis (Folkman, 1995; Folkman and D'Amore, 1996) . Since tumor growth and metastases are dependent on angiogenesis, antiangiogenic therapies have become important strategies to inhibit tumor progression. Recently, many approaches have been tried to develop antiangiogenic agents. VEGF-targeted drugs, epidermal growth factor (EGF) receptor tyrosine kinase inhibitors (Ciardiello and Tortora, 2002) , MMP inhibitors (Kerbel and Folkman, 2002) , and integrin-targeted drugs (Gutheil et al., 2000) have been developed for this purpose.
Intriguingly, receptors for VEGF have been identified on subsets of human breast cancers and breast cancer cell lines, suggesting that a potential VEGF-mediated autocrine growth effect might exist in such tumors (Price et al., 2001; Nakopoulou et al., 2002) . Receptors for VEGF have also been described in tumor cells from C3(1)/Tag transgenic mammary cancers (Calvo et al., 2002b) . Whereas antiangiogenesis indirectly inhibits tumor growth by impairing blood vessel formation, interference of an autocrine growth pathway on tumor cells could substantially augment the inhibition of tumor growth. VEGF, the angiogenic factor most commonly produced by tumors, binds to two distinct receptor tyrosine kinases (Xie et al., 1999) -the fms-like tyrosine kinase Flt-1 (VEGFR-1) and the kinase insert domain containing receptor KDR/Flk-1 (VEGFR-2). These two membrane receptor tyrosine kinases are predominantly expressed on endothelial cells. Flk-1 is essential for the development of hematopoietic and endothelial cells (Shalaby et al., 1995; Takahashi et al., 2001) , whereas Flt-1 is required more for differentiation and vascular organization (Fong et al., 1995) .
VEGF and VEGF signaling have been intensively studied for developing novel anticancer agents and many approaches have been taken, including small molecule tyrosine kinase inhibitors (Itokawa et al., 2002; Laird et al., 2002; Lin et al., 2002; Spiekermann et al., 2002) , fusion proteins (Holash et al., 2002) , ligand antibodies (Presta et al., 1997) , receptor antibodies (Zhu et al., 2003) , and ribozymes (Parry et al., 1999) . Antibodies directed against VEGF that bind specific epitopes can block VEGF interaction with its receptors (Presta et al., 1997) . Recombinant solubilized receptors containing the VEGF interaction domains of VEGFR-1 and VEGFR-2 fused to the Fc portion of immunoglobulin G1 bind VEGF and can prevent VEGF signaling through both VEGFR-1 and VEGFR-2 (Zhu et al., 2003) . Antibodies that target VEGFR-1 and VEGFR-2 also inhibit the VEGF signaling pathway (Zhu et al., 2003) . Ribozymes are RNA-based enzymes that bind to and cleave mRNA molecules in a sequence-specific manner (Parry et al., 1999) resulting in the destruction of message and decreased expression of the encoded protein. Anti-Flt-1 and/or anti-KDR ribozymes reduce mRNA levels specifically, decrease proliferation of vascular cells in culture, and inhibit VEGF-stimulated angiogenesis.
Endothelial cells, such as human umbilical vein cells (HUVECs), express high levels of Flk-1/KDR (VEGFR-2), but low levels of Flt-1 (VEGFR-1), and are responsive to VEGF for growth signaling. Compounds that can interfere with VEGF signaling by blocking the phosphorylation of Flk-1/KDR may be important agents to inhibit tumor angiogenesis. GW654652 has been developed as a small molecule inhibitor of VEGFRs autophosphorylation (Dev et al., 2003; Kumar et al., 2003) . A previous study has shown that GW654652 blocked VEGF-induced Flt-1 phosphorylation in a multiple myeloma cell line that expresses high-affinity VEGFR-1 but not VEGFR-2 (Podar et al., 2004) . Structurally, GW654652 belongs to the family of indazolylpyrimidines .
Ultimately, one wants to test the efficacy of an agent in a preclinical setting using an appropriate model system. The validation of genetically engineered mouse models for preclinical testing has become an important area of research. The C3(1)/Tag transgenic mouse model of mammary cancer shares important biological and histological similarities to human breast cancer (Maroulakou et al., 1994) . Female mice develop mammary gland tumors within a well-defined time course of lesion progression (Maroulakou et al., 1994; Shibata et al., 1996) developing through low-grade and high-grade mammary intraepithelial neoplasia (similar to human ductal carcinoma in situ) to invasive carcinoma with some mice developing metastases. VEGF and VEGF receptors, VEGFR-1 and VEGFR-2, are upregulated during the transition from preinvasive mammary lesions to invasive carcinomas (Calvo et al., 2002a) .
In this study, we demonstrate that GW654652 has potent antiangiogenic activity as well as inhibitory activity on VEGF-mediated autocrine growth of the tumor epithelial cells. GW654652 inhibits the growth of HUVEC and M6 cells (mammary tumor cells derived from the C3(1)/Tag model) and induces apoptosis. We also show that the compound is a potent inhibitor of angiogenesis in vivo using the chick chorioallantoic membrane (CAM) and Matrigelt plug assays. Most significantly, GW654652 can dramatically inhibit mammary cancer progression in the C3(1)/Tag mouse model of mammary cancer without apparent signs of toxicity. These results suggest that GW654652 or similar compounds may have potential use as an antiangiogenic agent for human breast cancer and may also function as an inhibitor of VEGF autocrine-mediated tumor growth.
Results

Inhibitory effect of GW654652 on VEGFRs kinase activities
The structure of GW654652 is depicted in Figure 1 . Kinase assays revealed that GW654652 was highly specific for inhibiting VEGFRs phosphorylation compared to other kinase receptors based upon IC 50 determinations (Table 1) . The IC 50 for VEGFR-2 was 0.0023 mM with concentrations of 1. 1-, 5.3-, 130-, 139-, 2086.9-, 156-, 605-, 5125- , and >8800-fold to produce an IC 50 for VEGFR-3, VEGFR-1, FGF-R1, FGF-R3, FGF-R4, epidermal growth factor receptor (EGFR), ErbB-2, and CDK-4, respectively. These results demonstrate that GW654652 has a high degree of specificity for inhibiting VEGFRs. 
GW654652 inhibits HUVEC and M6 cell proliferation
The effects of GW654652 on HUVECs and M6 cells (derived from a C3(1)/Tag transgenic mammary tumor; Holzer et al., 2003) were investigated in a proliferation assay using concentrations of GW654652 ranging from 0 to 0.1 mM (Figure 2a and b) . Cell growth was dramatically inhibited in both HUVEC and M6 cells.
To show the specificity of GW654652 to VEGFmediated growth, the cells were stimulated with either 10 ng/ml VEGF or 0.5 ng/ml basic fibroblast growth factor (bFGF), which are known to act as angiogenic factors. The inhibitory effect of GW654652 on VEGF stimulation of HUVECs proliferation was more selective for VEGF-induced proliferation than bFGF-induced proliferation at the same concentration. M6 cells were much less responsive to growth stimulation by VEGF, although GW654652 significantly inhibited proliferation. Since M6 cells already express relatively high endogenous levels of VEGF, the VEGF-specific response to GW654652 could not be demonstrated with the addition of exogenous VEGF. To determine the role of endogenous VEGF in M6 cell proliferation, we performed experiments in which endogenous VEGF was downregulated by small interfering RNA (siRNA). The level of VEGF mRNA was significantly reduced 24 h after siRNA transfection in M6 cells ( Figure 3a (Figure 3c ).
GW654652 increases apoptosis in HUVECs and M6 cells
To characterize potential mechanisms of growth inhibition by GW654652, the induction of apoptosis in HUVECs (Figure 4a and d) and M6 cells (Figure 4b , c, and e) in response to GW654652 was determined.
After 24 h incubation in serum-free medium, HUVECs were incubated for 24 h and M6 cells were incubated for 6 h with 0.05, 0.1 or 0.5 mM GW654652. Different incubation times were used for each cell line because of differences in the growth characteristics of the cells. FACS analysis demonstrated an accumulation of cells in the sub-2N stage, indicating that apoptosis occurred at all concentrations of GW654652 tested. For HUVECs, levels of apoptosis increased from 13% in the control samples to 32.0, 48.5, and 47.2% for cells exposed to 0.05, 0.1 or 0.5 mM GW654652, respectively ( Figure 4a and d, ***Po0.001). For M6 cells, the levels of apoptosis increased from 7.9% in the control samples to 14.1, 10.8, and 14.6% at 0.05, 0.1 or 0.5 mM GW654652, respectively ( Figure 4b and e, **Po0.01, *Po0.05). To observe the morphological changes in M6 cells, cells at 80% confluency were treated for 24 h with the same concentrations of GW654652 used for the FACS analyses. Morphological changes in M6 cells following GW654652 treatment were observed in a dose-dependent manner. As shown in Figure 4c , M6 Figure 4c ). To further confirm the apoptotic response, DNA fragmentation and caspase-8 activation were measured. DNA laddering was determined after 8 h of treatment with 0.l mM GW654652 (Figure 5a ). In order to investigate the kinetics of apoptosis in response to GW654652 in M6 cells, caspase-8 activation was determined. Caspase-8 activation increased about twofold in response to 0.1 mM GW654652 (**Po0.01, ***Po0.001). These results show that GW654652 increases apoptosis of M6 cells at least in part through caspase-8 activation.
Inhibition of VEGF-induced angiogenesis by GW654652 in the CAM and Matrigelt plug assays
The CAM and Matrigel plug assays were performed to test the inhibitory activity of GW654652 on angiogenesis ( Figure 6 ). Three concentrations of GW654652 -0.1, 0.5, and 1 mM, all delivered in a total volume of 2 ml -were tested in the CAM assay. Inhibition of VEGFinduced angiogenesis was demonstrated at the three concentrations compared to the VEGF-positive controls. A total of 66% of the VEGF control samples exhibited a positive angiogenic response in the CAM assay, whereas this was reduced to 16% at the highest dose of GW654652 (Figure 6a and c). We also evaluated the effect of the oral administration of GW654652 on the inhibition of angiogenesis using the Matrigel plug assay. In control plugs without VEGF, only a few scattered vascular cells were observed, whereas VEGF dramatically enhanced the number of vascular cells . Female C57BL/6 mice (8-week-old) were injected subcutaneously with 0.1 ml Matrigel or Matrigel with VEGF and animals were treated with GW654652 at 10, 30, and 100 mg/kg/day doses (described in Materials and methods). Four mice were used for each group and the blood vessels were counted in one random field from each plug. (c) Quantification of angiogenesis in the CAM assay. (d) The number of blood vessels per field was calculated in random fields from four mice/group in the Matrigel plug assay within the plugs. GW654652 significantly inhibited VEGF-induced angiogenesis in the plugs at all concentrations tested -10, 30, and 100 mg/kg/day -as seen in Figure 6b and d (positive control vs 100 mg/kg/day GW654652-treated group, Po0.001). These data demonstrate that GW654652 inhibits VEGF-induced angiogenesis in two in vivo model systems and that it is effective as an oral agent.
Immunohistochemical analysis of VEGF, VEGFR-2, and CD-31 in C3(1)/Tag mice Mammary glands were collected from 15-week-old mice after 3 weeks of daily oral treatment with GW654652. Both VEGF and VEGFR-2 were detected by immunohistochemistry in the mammary intraepithelial neoplastic (MIN) lesions (Figure 7a ). No differences in staining of VEGF and VEGFR-2 were observed among the three groups. Microvessel density (MVD; as detected by anti-CD-31 immunostaining) in mammary tumors from 20-to 25-week-old mice was reduced by more than 50% in the group that received 100 mg/kg/day of GW654652 compared to control animals ( Figure 7b and c, **Po0.01). No discernible differences were found at the lower dose of 10 mg/kg/day. These data demonstrate that GW654652 is effective in reducing tumor vasculature in vivo after oral treatment.
GW654652 delayed tumor onset, reduced tumor volume and multiplicity, and increased survival of female C3(1)/ Tag transgenic mice
Tumor onset was moderately, but significantly, delayed in mice that received 100 mg/kg/day of GW654652, whereas the group that received 10 mg/kg/day did not show a significant difference in tumor onset compared to controls ( Figure 8a ) (P ¼ 0.0069, control vs 100 mg/ kg/day GW654652-treated group). Tumor volume was greatly reduced in mice that received 100 mg/kg/day of GW654652 compared to controls (Figure 8b ). At 20 weeks of age, the average tumor volume for the highdose group was 150 mm 3 , whereas the group of mice given 10 mg/kg/day of GW654652 and controls showed an average tumor volume of 850 mm 3 . Thus, a decrease of 82% in tumor volume was achieved with GW654652. At 23 weeks of age, when all of the control mice were dead, the reduction in tumor volume in GW654652-treated mice was approximately 50% relative to the largest tumors observed at the time of death of the untreated mice (**Po0.01, *Po0.05). Tumor number was also significantly reduced in mice treated with GW654652 (Figure 8c ). At 19 weeks of age, the mean number of tumors/mouse was less than 0.5 in mice treated with 100 mg/kg/day of GW654652, whereas the mean number of tumors in control mice was almost 2.0/ mouse. In this case, mice treated with 10 mg/kg/day of GW654652 showed intermediate values between controls and mice treated with 100 mg/kg/day of GW654652 (**Po0.01, *Po0.05). The survival of the mice was significantly increased by 5 weeks in animals treated with 100 mg/kg/day of GW654652, with respect to the control group ( Figure 8d ) (P ¼ 0.0022). After cessation of treatment with GW654652 at 20 weeks of age, tumors began to grow rapidly (Figure 8b ). At 20 weeks of age, when treatment with GW654652 was stopped, all mice treated with 100 mg/kg/day were alive, whereas only 50% of mice treated with either phosphate-buffered saline (PBS) or 10 mg/kg/day of GW654652 were alive at the same age. These data demonstrate that GW654652 reduced tumor growth and multiplicity resulting in increased survival, which appeared limited by the duration of treatment. No differences in weights were observed between treated and untreated mice and no signs of toxicity were observed at the doses tested. Histopathologic analyses of livers from all mice revealed no abnormalities in the treated groups. 
Discussion
Protein kinases play an important role in signal transductions that regulate a number of cellular functions such as differentiation and proliferation. Therefore, targeting of protein kinases, especially tyrosine kinases, might provide new and complimentary therapies for cancer (Shawver et al., 2002; Traxler, 2003) . Small molecule drugs targeted against different tyrosine kinases have been intensively developed, including EGFR (Traxler, 2003) , platelet-derived growth factor receptor (PDGFR), Kit, and Fms-like tyrosine kinase (Flt-3) (Laird et al., 2002) . Solid tumors cannot grow beyond a certain size without inducing the formation of new blood vessels (Folkman and D'Amore, 1996) . Selective VEGFR kinase inhibitors will suppress tumor growth by inhibiting tumor vascularization. GW654652 was developed to specifically inhibit VEGFRs phosphorylation Podar et al., 2004) . Several tyrosine kinase inhibitors have been shown to have varying degrees of efficacy in clinical trials for cancer therapy (Shawver et al., 2002) . GW654652 adds an additional dimension to target VEGFRs, which could be beneficial against many forms of cancer.
Recent studies have demonstrated that VEGF receptors are found on human breast cancer epithelial cells (Price et al., 2001; Nakopoulou et al., 2002) , which also produce VEGF, suggesting that tumor cells may generate an autocrine growth mechanism to their advantage. Mammary tumor cells from the C3(1)/Tag model also express high levels of VEGFR-2 (Flk-1/ KDR) and VEGFR-1 (Flt-1) (Calvo et al., 2002b) . In this study, we demonstrate for the first time that a selective VEGFRs inhibitor, GW654652, has a profound effect on spontaneous mammary cancer growth in a transgenic mouse model. Our results demonstrate that this compound targets vascularization as well as growth of the tumor epithelial cells.
We have shown that inhibition of proliferation by GW654652 in HUVEC and M6 tumor epithelial cells occurs in a dose-dependent manner at concentrations that can be achieved in vivo. The inhibition of proliferation in HUVECs by GW654652 was VEGFresponsive, but the inhibition of M6 cell proliferation (previously derived from a C3(1)/Tag transgenic mammary tumor; Holzer et al., 2003) was not affected by supplementation with VEGF. This difference in response to VEGF between HUVECs and M6 cells is likely due to the relatively high levels of VEGF endogenously produced by M6 cells, leading to a potential autocrine growth effect. Therefore, additional VEGF does not significantly increase proliferation of M6 cells, but GW654652 does significantly inhibit proliferation signaled through VEGF.
Epithelial cells in the normal mammary gland secrete very low amounts of VEGF to maintain the integrity of blood vessels, but in mammary carcinomas upregulation of VEGF results in increased angiogenesis accompanied by overexpression of the VEGF receptors VEGFR-1 and VEGFR-2 (Heer et al., 2001) . A significant correlation between high levels of VEGF and increased KDR/Flk-1 activity associated with increased Ki-67 expression in hormone-induced mammary cancer suggests that VEGF may act as an autocrine growth factor for human mammary cancer cells in vivo and that this autocrine regulatory role may be mediated through VEGFR-2 (Nakopoulou et al., 2002) . Our immunohistochemical results are consistent with an autocrine activation of VEGF signaling in the C3(1)/ Tag transgenic mammary cancer model since VEGF and VEGFR-2 are expressed strongly in MIN lesions. siRNA against mouse VEGF significantly inhibited proliferation of M6 cells, strongly suggesting that endogenously produced VEGF in M6 cells has a positive autocrine growth effect on these cells. By reducing endogenous VEGF using siRNA, the inhibitory effect of GW654652 was even more pronounced in M6 cells. VEGF has been shown to act as an autocrine factor for the survival of metastatic breast carcinoma cells in vitro and is associated with breast carcinoma invasion (Nakopoulou et al., 2002) . This is the first transgenic model shown to recapitulate this important autocrine growth mechanism identified in human breast cancer.
Regarding the mechanism of cell growth inhibition, our kinase assays show that GW654652 is highly specific for VEGFR-2. The IC 50 for VEGFR-3 (0.0025 mM) is also similar to that found for VEGFR-2. In spite of the specificity of GW654652 for VEGFR-2 compared to other receptor kinases, we cannot exclude the possibility that GW654652 may also exert an inhibitory effect through other non-VEGFR-2 pathways. A recent study demonstrated that GW654652 inhibited the growth and migration of multiple myeloma cells, which express VEGFR-1 but not VEGFR-2 (Podar et al., 2004) . Such a result has also been found for other small molecules targeting VEGF receptors. For instance, SU5416, SU6668, and SU11248 appear to have inhibitory activity on VEGF, FGF, and PDGF receptors, thus, potentially broadening the range of molecular targets (Itokawa et al., 2002; Laird et al., 2002; Spiekermann et al., 2002) . Although SU5614 is a potent inhibitor of VEGF-induced endothelial cell sprouting in vitro, the sensitivity of leukemic cells toward the growth inhibitory activity of the compound is dependent upon c-kit, not VEGFR-1/2 expression (Spiekermann et al., 2002) .
Our study demonstrates that GW654652 induces apoptosis in both HUVECs and M6 cells followed by a cell growth arrest at the G1 phase of the cell cycle. We also show that GW654652 induces DNA fragmentation and caspase-8 activity in M6 cells during apoptosis. Other antiangiogenic factors have also been shown to regulate apoptosis. For example, 2-methoxyestradiol, an endogenous compound with antiangiogenic activity, triggers apoptosis in various tumor cell lines (Pribluda et al., 2000; Qanungo et al., 2002) . The cell lines responsive to 2-methoxyestradiol undergo apoptosis either by G2-M arrest with Bcl-xL phosphorylation or through the accumulation of tetraploid cells in the G1-S phase without Bcl-2/Bcl-xl phosphorylation. These results suggest that GW654652 can suppress tumor progression, in part, through the activation of apoptosis in tumor cells as well as endothelial cells.
In the present study, we have demonstrated that tumor vascularization is significantly decreased in animals that received GW654652 as compared to control animals. We conclude that inhibition of tumor growth is caused, in part, by the reduced number of tumor vessels in GW654652-treated mice. GW654652 treatment resulted in significant improvement in all parameters related to tumor growth in vivo and significantly increased animal survival. This effect was clear in the animals receiving the highest dose of GW654652, whereas mice treated with a low dose of GW654652 (10 mg/kg/day) had little or no benefit. Lowdose GW654652 was, however, able to inhibit angiogenesis in the Matrigel plug assay. Additional doses and longer treatment of GW654652 were not tested due to the limited amount of compound available. Once treatment was terminated, tumor progression occurred quickly in this mouse model, demonstrating that the interference of VEGF signaling in this model did not permanently inhibit tumor growth, but rather provided a static growth effect during its period of administration. These results are consistent with the hypothesis that chronic administration of antiangiogenic drugs will be required for a maximal, sustained effect, and that these compounds may be most efficacious when given in combination with drugs that target additional oncogenic pathways. Ongoing studies will determine whether longterm administration of GW654652 would continue to inhibit tumor growth or whether resistance to the compound would develop.
Of significance is the fact that no apparent toxicity was noted in animals that received this compound during the course of these experiments. Livers from all treated and untreated mice were also examined microscopically and no histological abnormalities were observed in the treated group. While potential toxic effects are not excluded by these studies, further investigations involving GW654652 appear warranted since the development of some kinase inhibitors has been terminated because of toxicities in clinical trials.
Our previous studies have demonstrated that additional molecular targets can be used to interfere with tumor angiogenesis in the C3(1)/Tag mammary cancer model, including endostatin (Yokoyama et al., 2000; Calvo et al., 2002a, b) and 2-methoxyestradiol (et al., unpublished observations). The data presented in this study demonstrate that interference of the VEGF signaling pathway using GW654652 has a significant effect on tumor growth inhibition and on prolongation of survival. This work may have important implications for translating antiangiogenic therapy to human breast cancer. Future studies will address how combination therapies may improve these parameters even further by targeting different pathways involved in angiogenesis, tumor growth, and survival.
Materials and methods
Reagents
GW654652 was discovered and synthesized by GlaxoSmithKline (Research Triangle Park, NC, USA). For in vitro and in vivo assays, a stock solution of 1 mM GW654652 was prepared in dimethylsulfoxide (DMSO).
Kinase assays
Kinase activities for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1, FGFR-2, FGFR-3, SRC, Eph-B4, c-Fms, Tie-2, EGFR, ErbB-2, CDK-2, and CDK-4 were conducted as previously described .
Cell lines
M6 cells, which were derived from C3(1)/Tag transgenic mice mammary gland tumors (Holzer et al., 2003) , were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and penicillin/streptomycin. HUVECs (less than passage 7) were obtained from freshly delivered umbilical cords by treatment with 0.1% collagenase (Jaffe et al., 1973) . Cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 20% bovine calf serum (BCS) (Hyclone, Logan, UT, USA), 2 mM glutamine, 0.1 mg/ml heparin (Sigma-Aldrich, St Louis, MO, USA), penicillin/streptomycin, and 0.05 mg/ml endothelial cell growth supplement (SigmaAldrich, St Louis, MO, USA) at 371C and 5% CO 2 .
Cell proliferation assay
HUVECs or M6 cells were seeded at 3 Â 10 3 cells/well in flatbottom collagen-coated or uncoated 96-well plates (Beckton Dickinson, Mansfield, MA, USA), in quadruplicate and allowed to adhere overnight. GW654652 (final concentrations from 0 to 0.1 mM), in serum-free medium for M6 cells and 1% FCS for HUVECs, was added to each well. After a 30 min incubation with GW654652, cells were subsequently stimulated with 10 ng/ml VEGF (R&D Systems, Minneapolis, MN, USA) or 0.5 ng/ml bFGF (R&D Systems, Minneapolis, MN, USA). M6 cells were incubated for 24 h and HUVECs for 72 h at 371C. Proliferation was measured using the WST-1 reagent (Roche Molecular Biochemicals, Mannheim, Germany). A 10 ml portion of WST reagent was added to each well and the cells were incubated for 4 h at 371C. Absorbance at 405 nm was measured using an ELISA plate reader. All the experiments were performed at least three times.
siRNA transfection siRNA against mouse VEGF (siVEGF) was employed from a previous study (Reich et al., 2003) . siVEGF target sequence is AACGAUGAAGCCCUGGAGUGC. Sense sequence is CGAUGAAGCCCUGGAGUGC and antisense sequence is GCACUCCAGGGCUUCAUCG. Green fluorescent protein duplex (GFP) was used as a control. The target sequence is GGCTACGTCCAGGAGCGCACC. M6 cells (0.5 Â 10 5 ) were plated in six wells with 2% FBS without antibiotics the day before transfection. siRNAs were synthesized by Dharmacon Inc. siRNA was transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Transfected cells were incubated for 24 h at a 371C incubator. Conditioned media from each well were collected to measure the concentration of VEGF protein by ELISA analysis. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) from the same wells for semiquantitative RT-PCR. GW654652 was added at 0.01, 0.05, and 0.1 mM concentrations 24 h after siVEGF transfection to determine the autocrine effect of endogenous VEGF in M6 cells following stimulation with 10 ng/ml VEGF on cell proliferation. All the experiments were repeated at least twice.
Reverse transcription-polymerase chain reaction
RT reactions were performed using the Superscriptt firststrand synthesis system for RT-PCR (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions: 1 mg total RNA, 1 ml of 10 mM dNTP mix, and 1 ml of oligo(dT)12-18 (0.5 mg/ml) in a total volume of 10 ml at 651C for 5 min, followed by the addition of 2 ml of 10 Â RT buffer, 4 ml of 25 mM MgCl 2 , 2 ml of 0.1 M DTT, 1 ml of RNaseOUTt (40 U/ml) with incubation at 421C for 2 min. Reverse transcriptase (50 U) was added and incubated at 421C for 50 min. The reaction was terminated at 701C for 15 min and then chilled on ice. A 1 ml portion of RNase H (2 U/ml) was added to each tube and incubated for 20 min at 371C.
PCR mixture included 1 ml of the cDNA generated from the RT reaction, 1 ml of 10 Â PCR buffer, 1.5 ml of 50 mM MgCl 2 , 1 ml of 10 mM dNTP, 0.4 ml of Taq polymerase (5 U/ml), 0.5 ml of 20 mM sense primer, and 0.5 ml of 20 mM antisense primer in a total volume 50 ml. PCR conditions were as follows: 40 cycles of 941C 5 min/941C 30 s; 551C 30 s; 721C 1 min/721C, 7 min, 41C. The following primer sequences were used: VEGF sense 5 0 -CTGCTCTCTTGGGTGCACTG-3 0 and antisense 5 0 -CACCGCCTTGGCTT GTCACA-3 0 ; GAPDH sense 5 0 -ATCACCATCTTCCAGGAGCGAGAC-3 0 and antisense 5 0 -ATGCCAGTGAGCTTCCCGTTCAGC-3 0 .
ELISA analysis
M6 cells ( 10 6 ) were plated in six wells and the next day transfected with GFP or siVEGF. After 24 h transfection, the conditioned media were collected for VEGF protein measurement using a quantitative sandwich enzyme immunoassay (Quantikine; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
FACS analysis
After 24 h in serum-free medium, HUVECs were incubated for 24 h, and M6 cells were incubated for 6 h with 0.05, 0.1 or 0.5 mM GW654652. Cells were trypsinized and resuspended in 2 ml PBS containing 1 mM EDTA. The cells were collected following centrifugation and washed once with PBS. Cells were resuspended in 2 ml ice-cold 80% ethanol and placed on ice for 30 min. Cells were washed once with PBS and the cell pellet was resuspended in 1 ml propidium iodide (PI) (SigmaAldrich, St Louis, MO, USA) staining buffer (50 mg/ml PI and 25 mg/ml RNase A; Roche Molecular Biochemicals, Mannheim, Germany) in permeability buffer (0.1% Triton X-100/0.1 mM EDTA in PBS).
The samples were analysed using FACSCalibur (Becton Dickinson, Mansfield, MA, USA) within 24 h after preparation and the data were analysed with CellQuest software (Becton Dickinson, Mansfield, MA, USA).
DNA fragmentation
M6 cells (1 Â 10 6 ) were plated in six wells and grown overnight until they attached. The medium was changed to serum-free medium and 0.1 mM GW654652 was added for 2, 4, 8, and 12 h and harvested by spinning at 1000 r.p.m. for 10 min. Cell pellets were washed with PBS, resuspended in lysis buffer (10 mM Tris pH 7.5, 1 mM EDTA, 0.2% Triton X-100) and incubated at room temperature for 15 min. After centrifugation, the supernatant was transferred to a new tube and 55 ml of 10% SDS, 5 ml of 10 mg/ml RNase A (Roche Molecular Biochemicals, Mannheim, Germany), and 5 ml of 20 mg/ml proteinase K (Sigma, St Louis, MO, USA) were added and incubated at 371C for 45 min. DNA was extracted and resuspended in 20 ml of 100 mg/ml RNase A and incubated for 15 min at 371C and then run on a 1.5% agarose gel stained with SYBR green I (Molecular Probes Inc., Eugene, OR, USA).
Measurement of caspase-8 enzymatic activity
Caspase-8 activity was measured using a caspase colorimetric protease assay kit (R&D Systems, Minneapolis, MN, USA). Briefly, after treatment of cells with 0.01, 0.05, and 0.1 mM GW654652 for 8 h, cells were harvested and pelleted. Lysis buffer was added to the cell pellets. Resuspended cells were incubated on ice for 10 min and then centrifuged to remove insoluble materials. Cell lysates were incubated with 5 ml of 1 mM stock of substrate at 371C for 2 h. The release of 7-amino-4-trifluoromethyl coumarin (AFC) was measured with an ELISA reader at 405 nm. Assay was repeated three times.
Chick chorioallantoic membrane assay
Approximately 4 ml of albumin was removed from 3-day-old embryonated eggs (CBT Farms, Chestertown, MD, USA). On day 5, windows were opened in the shell for each egg and covered with tape to prevent drying, and then further incubated at 371C. On day 7, 2 ml of solution containing 50 ng human VEGF (hVEGF) and either 0.1, 0.5, or 1 mM GW654652 was applied to the center of quartered 13-mmdiameter plastic coverslips (Nalge Nunc International, Rochester, NY, USA) and air dried. hVEGF (50 ng) served as a positive control. DMSO (2.5 ml) served as a negative control. Each coverslip was put on the CAM, and the eggs were incubated at 371C for 3 days. Angiogenic response was then scored as either positive or negative and photographed (Ponce et al., 2001) .
Matrigel plug assay
A 1 ml portion of Matrigelt (Becton Dickinson Labware, Bedford, MA, USA) alone or mixed with 50 ng mVEGF was injected subcutaneously into female 8-week-old C57BL/6 mice. The same concentration of mVEGF was employed as that described in a previous paper (Inoki et al., 2002) . The mice were treated with GW654652 (0, 10, 30, and 100 mg/kg/day) by oral gavage for 7 days. On day 7, the mice were killed and the plugs were harvested, fixed in formalin, and stained with Masson trichrome blue. Four mice were used in each group. One field from each sample was selected randomly and blood cells were counted to evaluate vascularization of the plugs as described previously (Inoki et al., 2002) .
Animal studies
Heterozygous C3(1)/Tag transgenic female mice (12-week-old) in the FVB/N background were used for these studies and have been previously described (Maroulakou et al., 1994) . The mice were divided into three groups: (1) control group that received PBS (n ¼ 16); (2) group that received 10 mg/kg/day of GW654652 (n ¼ 16); and (3) group that received 100 mg/kg/ day of GW654652 (n ¼ 16). GW654652 was suspended in hydroxypropyl methyl cellulose (HPMC) (Sigma-Aldrich, St Louis, MO, USA) containing 0.1% Tween 80 (Sigma-Aldrich, St Louis, MO, USA) in water as a vehicle. GW654652 was administered to the mice by oral gavage daily for 8 weeks beginning at 12 weeks of age (a stage when MIN lesions have developed). The control group of mice received PBS with the same schedule and route of administration from each group. Tumor incidence, burden (calculated volume ¼ the largest diameter Â (the smallest diameter) 2 Â 0.4; Calvo et al., 2002b) , and number were measured weekly. Five mice were killed at 15 weeks of age and mammary glands were fixed in 4% paraformaldehyde, embedded in paraffin, and cut for immunohistochemical analyses. For CD-31 immunohistochemistry, tumor samples from 20-to 25-week-old mice were immediately immersed in optimal cutting temperature (OCT) compound (Tissue-Tek, Sakura, Japan) and frozen on a mixture of dry ice and isopentane (Fluka, St Louis, MO, USA). All mice were treated in accordance with the guidelines of the Animal Care and Use of Laboratory Animals (NIH Publication No. 86-23, 1985) under an approved animal protocol.
Immunohistochemistry
Paraffin sections were rehydrated through decreasing concentrations of ethanol. Slides were immersed in citric acid (pH 6) and heated in a microwave oven twice for 5 min. Anti-VEGF antibody (sc-507, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at a 1 : 200 dilution. Anti-Flk-1 antibody (sc-315, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at a 1 : 400 dilution.
To detect MVD, cryostat-cut sections were immersed in citric acid (pH 6) and heated in a microwave oven twice for 5 min for antigen retrieval. Slides were stained with anti-CD-31 antibody (PharMingen, San Diego, CA, USA) at a 1 : 150 dilution. The avidin-biotin complex method (Vectastatin ABC Elite kit; Vector Laboratories, Burlingame, CA, USA) was used to visualize the bound antibody. Immunostaining for CD-31 (PECAM) was used for quantification of vascular density of tumors. Images from four fields randomly chosen were captured from each tumor sample using a Nikon Eclipse E800M microscope. Mammary tumors from five mice at approximately 20-25 weeks of age in each experimental group were examined, providing 20 fields per group for analyses. Image capture and analysis were performed with the Analy-SIS s software (Soft Imaging System, Lakewood, CO, USA) using the same light and color conditions for all the samples at Â 200. The brown signal from CD-31 immunostaining was filtered using the same filtering conditions for all of the samples. The area fraction (area occupied by the CD-31 staining divided by reference area) was calculated. Data are presented as the mean percentage of area occupied by CD-31 staining with respect to the total tumor area.
Statistical analysis
A one-way ANOVA was used to compare the mean area occupied by CD-31 staining between the three experimental groups and for quantification of blood vessels from the Matrigel plug assay. Neuman-Keuls analysis was used as a post hoc test. The two-sided Student's t-test was used to evaluate whether significant differences existed between the mean values of the groups analysed for the apoptosis assay. The log-rank test was used to determine differences in tumor onset and survival curves.
Abbreviations HUVEC, human umbilical vein endothelial cells; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; Tag, simian virus 40 T-antigen.
